Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

Search

Search results

The TransferAllianz proposes 5 measures to leverage the innovation potential of academic research and drive sustainable economic recovery following the corona crisis.

[Translate to English:]

Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.

[Translate to English:]

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

A research team at the German Center for Neurodegenerative Diseases (DZNE) has received the ‘Hugo Junkers Award for Research and Innovation from Saxony-Anhalt 2019’.

Ascenion has supported the 20 parties of the European LifeTime research consortium in agreeing the legal framework for their scientific cooperation.

Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has supported the conclusion of an agreement between the MDC and Fate Therapeutics, Inc.

Should public research institutes and universities receive equity in start-ups founded to commercialize their intellectual property? And if so, how…

This year’s innovation prize from the Metropolregion Mitteldeutschland goes to a team that has brought a novel anti-tuberculosis compound all the way…

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with…

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a licence…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding…

This year’s technology transfer award from Braunschweig’s Chamber of Industry and Commerce goes to scientists at the Helmholtz Centre for Infection…

Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment…

Ascenion’s partner institute, the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI), has joined forces with the…

 

Shire’s VEYVONDI received EU market authorization for the treatment of bleeding events and the prevention or treatment of surgical bleeding in…

Ascenion has negotiated a licence agreement between Medical School Hannover (MHH) and its spin-off Cardior Pharmaceuticals providing the company with…

Ascenion, the knowledge and technology transfer partner of the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), has negotiated an agreement with Roche…

The U.S. Food and Drug Administration (FDA) has extended the scope of Shire’s VONVENDI to include perioperative management of bleeding in adults with…

Making cancer surgery more precise

23 October 2017, Munich – SurgVision BV, a spin-off from the Helmholtz Zentrum München, has been acquired by…

9 October 2017, Munich – Last week Ascenion GmbH and the Medical University of Innsbruck launched their cooperation with a joint kick-off event. The…

Three further research institutes have decided to enter into partnership with Ascenion in recent months. This brings the number of long-term partner…

Unique RNA-based approach for the treatment of heart diseases

11 May 2017, Munich – Cardior Pharmaceuticals has completed a EUR 15 million Series A…

A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…

Heidelberg Pharma, a subsidiary of Wilex AG, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have signed a…

LentiBOOSTTM, an innovative gene therapy adjuvant, has got the green light from the FDA for use in a Phase III clinical trial. The technology, which…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…

19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz…

For the first time, a German team has won the world’s biggest life-science start-up competition. Captain T Cell, founded by Dr Felix Lorenz and…

Cancer-fighting gene therapy

A ground-breaking approach to the therapy of HIV infection has been published in the current issue of Nature Biotechnology: a designer recombinase…

Flexible funds from technology transfer

21 December 2015, Berlin and Munich - ‘VONVENDI [von Willebrand factor (Recombinant)]’, the new drug from Baxalta Incorporated, a global…

The US biotech company Amgen announced at the end of November that its cancer therapy BLINCYTO® has been approved by the European Commission for the…

From 40 submitted projects – all excellent, according to the jury – five have now emerged as winners. These were chosen as having the potential to…

Ascenion’s portfolio company OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has received further funding of…

Ascenion takes equity in the MHH start-up Zellkraftwerk

BigChem GmbH was founded this October to commercialize validated IT products and services developed at the Helmholtz Zentrum München. The research was…

The negotiation of a licensing and cooperation agreement between Formula Pharmaceuticals and the Helmholtz Association’s Max Delbrück Center for…